Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 12, 2012, details the completion of the acquisition of EUSA Pharma Inc. ("EUSA") by Jazz Pharmaceuticals Plc (the "Company") and the entry into a new material credit agreement to finance the transaction. The Company is organized under the laws of Ireland.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Total cash paid at closing was $680 million, comprising a $650 million base purchase price and approximately $30 million in working capital and liability adjustments.
- Contingent Payment: An additional potential cash payment of $50 million is due if EUSA's lead product, Erwinaze, achieves U.S. net sales of $124.5 million in 2013.
- Escrow: $50 million of the closing payment was deposited in an escrow account for 12 months to secure indemnification rights.
- Debt Financing:
- Term Loan Facility: $475 million, six-year term.
- Revolving Credit Facility: $100 million, five-year term (includes $10 million swing line and $10 million letter of credit subfacilities).
- Interest Rates:
- Term Loan: LIBOR + 4.25% (1.0% floor) or Prime + 3.25% (2.0% floor).
- Revolving Credit: LIBOR + 4.00% or Prime + 3.00% (subject to reduction based on leverage ratio).
- Use of Proceeds: Term loan proceeds were used to finance the EUSA acquisition, repay EUSA's existing indebtedness, and pay related fees.
Material Changes and Covenants
The Company has significantly increased its debt load to fund the EUSA acquisition. The new Credit Agreement imposes strict financial covenants, including a maximum secured leverage ratio. Key repayment terms include:
- Amortization: The Term Loan amortizes annually at 5% (Year 1), 7.5% (Year 2), 10% (Years 3-4), and 15% (Years 5-6).
- Mandatory Prepayments: Required from asset sale proceeds, debt issuances, and excess cash flow (starting fiscal year 2013). Excess cash flow prepayment percentages range from 0% to 75% depending on the secured leverage ratio.
- Collateral: Obligations are secured by a perfected security interest in substantially all tangible and intangible assets of the Loan Parties and 65% of the capital stock of certain subsidiaries.
Outlook, Risks, and Contingencies
The transaction introduces significant financial leverage and covenant compliance risks. Events of default include failure to make payments, breach of covenants, insolvency, or a change in control. If a default occurs, lenders may terminate commitments and declare all obligations immediately due and payable. The Company notes that pro forma financial information and financial statements of the acquired business will be filed within 71 days of this report.
Investor Verification Checklist
- Verify the final purchase price adjustments and the specific amount of EUSA's existing debt repaid.
- Review the full text of the Credit Agreement (Exhibit 10.1) for detailed covenant definitions and leverage ratio calculations.
- Monitor the upcoming filing of pro forma financial information to assess the combined entity's liquidity and leverage position.
- Track the sales performance of Erwinaze in 2013 to determine the likelihood of the $50 million contingent payment.
- Confirm the status of the $50 million escrow account and any potential indemnification claims.